Category: 78902-09-7

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 78902-09-7, name is 2-(2,2-Diethoxyethyl)isoindoline-1,3-dione, introducing its new discovery. Recommanded Product: 78902-09-7

Fast and effective reduction of nitroarenes by sodium dithionite under PTC conditions: Application in solid-phase synthesis

Herein, conditions for the fast and effective reduction of aromatic nitro groups bound to hydrophobic polystyrene-based Wang and Ring resins utilizing sodium dithionite in dichloromethane-water under PTC conditions are reported. Tetrabutylammonium hydrogen sulfate (TBAHS) was found to be an effective phase-transfer catalyst for this reaction. This method allows for the reduction of nitro groups to amino groups under mild conditions with complete conversion and is tolerant of other functional groups. This method is a superior alternative to tin(II) chloride-based reduction, which is known for its shortcomings.

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 78902-09-7 is helpful to your research. Recommanded Product: 78902-09-7

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Reference of 78902-09-7, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 78902-09-7, Name is 2-(2,2-Diethoxyethyl)isoindoline-1,3-dione,introducing its new discovery.

The synthesis of beta-nitropyridine compounds

Pyridine and a number of substituted pyridines have been nitrated by reaction with N2O5 followed by reaction with an aqueous solution of SO2xH2O or NaHSO3. The dependence of the yields on the pH of the aqueous reaction medium, on the concentration of SO2xH2O-HSO3-, on addition of methanol to the aqueous phase, and on the reaction temperature were investigated. The yields obtained with NaHSO3 were: 3-nitropyridine 77%, 2-methyl-5-nitro-pyridine 36%, 3-methyl-5-nitropyridinc 24%, 3-acetyl-5-nitropyridine 18%, 5-nitropyridine-3-carboxylic acid 15%, 3-chloro-5-nitropyridine 11%, 4-methyl-3-nitropyridine 39%, 4-acetyl-3-nitropyridine 67%, 4-cyano-3-nitropyridine 45%, 4-phenyl-3-nitropyridine 68%, 4-formyl-3-nitropyridine 62% (from reaction in liquid SO2), 3-nitropyridine-4-carboxylic acid 48%, methyl 3-nitropyridine-4-carboxylate 75%, 2,3-dimethyl-5-nitropyridine 37%, 2,4-dimethyl-5-nitropyridine 64%, 3-nitroquinoline 10% and 4-nitroisoquinoline 42%.

If you¡¯re interested in learning more about 16096-33-6, below is a message from the blog Manager. Reference of 78902-09-7

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

78902-09-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.78902-09-7,2-(2,2-Diethoxyethyl)isoindoline-1,3-dione,as a common compound, the synthetic route is as follows.

2-{2-ethoxy-2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]ethyl}-1H-isoindole-1,3(2H)-dione (Compound 42) To 50 ml dichloromethane solution of 2-(2,2-diethoxyethyl)-1H-isoindole-1,3(2H)-dione (6.8 g, 25.8 mmol) under an ice bath was added 2,6-lutidine (9.89 mL, 85 mmol) and TMSOTf (10.3 mL, 56.8 mmol). The reaction stirred under the ice bath for one hour. After which, (9Z,12Z)-octadeca-9,12-dien-1-ol (24.3 mL, 77 mmol) was added in and the reaction was stirred from 0 C. to 20 C. for 16 hours. The reaction was diluted with 200 mL dichloromethane and washed by 100 mL of NaHCO3 solution, water, brine. The organic was dried over Na2SO4, filtrated and purified by silica gel chromatography (0% ethyl acetate/hexane?18% ethyl acetate/hexane) to give title compound (12.1 g). MS 506.5 (M+Na).

The synthetic route of 78902-09-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SIRNA THERAPEUTICS, INC.; Colletti, Steven L.; Deng, Zhengwu James; Stanton, Matthew G.; Wang, Weimin; Hills, Ivory; (47 pag.)US9670487; (2017); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI